WO2009144286A1 - Pharmaceutical compositions comprising brivaracetam - Google Patents

Pharmaceutical compositions comprising brivaracetam Download PDF

Info

Publication number
WO2009144286A1
WO2009144286A1 PCT/EP2009/056570 EP2009056570W WO2009144286A1 WO 2009144286 A1 WO2009144286 A1 WO 2009144286A1 EP 2009056570 W EP2009056570 W EP 2009056570W WO 2009144286 A1 WO2009144286 A1 WO 2009144286A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
tablet
composition according
core
brivaracetam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/056570
Other languages
French (fr)
Inventor
Frédéric EECKMAN
Monique Berwaer
Domenico Fanara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39714168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009144286(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES09753941.5T priority Critical patent/ES2465478T3/en
Priority to PL09753941T priority patent/PL2285357T3/en
Priority to DK09753941.5T priority patent/DK2285357T3/en
Priority to JP2011511013A priority patent/JP5553452B2/en
Priority to CA2722093A priority patent/CA2722093C/en
Application filed by UCB SA filed Critical UCB SA
Priority to US12/993,704 priority patent/US8435564B2/en
Priority to CN200980120221.XA priority patent/CN102046153B/en
Priority to BRPI0912161A priority patent/BRPI0912161A2/en
Priority to HK11107321.2A priority patent/HK1153141B/en
Priority to EP09753941.5A priority patent/EP2285357B8/en
Publication of WO2009144286A1 publication Critical patent/WO2009144286A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • compositions comprising Brivaracetam
  • the present invention relates to a novel pharmaceutical composition comprising Brivaracetam.
  • Brivaracetam is effective in the treatment of epilepsy.
  • Clinical trials evaluated the efficacy and safety of Brivaracetam (5, 20, 50 and 150 mg per day) in the adjunctive treatment of adult patients (16-65 years) with refractory partial onset seizures, with or without secondary generalization.
  • One of the objectives currently sought in the development of pharmaceutical compositions which can be administered orally is to control the release of pharmaceutically active substances so that they can be administered in a few daily doses, ideally in a single daily dose.
  • Brivaracetam is a very water soluble active ingredient (ca. 700 mg /ml), and it is not obvious to slow down the release of the drug.
  • the resulting in vitro dissolution (USP ⁇ 71 1 > apparatus n °2) in a bufferred aqueous media has to show a drug release of no more than 40% after 1 hour of dissolution, of 35% - 80% after 4 hours of dissolution and of no less than 80% after 16 hours of dissolution.
  • the present invention relates to a pharmaceutical composition in the form of a tablet comprising, as active ingredient, Brivaracetam and, as excipient within the core of the tablet, 5% to 80% per weight of at least one hydrophilic matrix agent, with respect to the total weight of the core of the tablet.
  • active ingredient as used herein is defined as a substance which has a therapeutic effect.
  • the amount of the active ingredient present in the pharmaceutical composition of the invention may vary depending on the patient to which the compositions are administered and on the specific disease to be treated.
  • core of the tablet is defined as the pharmaceutical composition without coating. All the percentages are given per weight of the total weight of the core of the tablet, except when it is written otherwise.
  • hydrophilic matrix agent as used herein is defined as a pharmaceutical acceptable excipient which generates a gel in contact to water.
  • a “hydrophilic matrix agent” is a material that is a water dispersible rate controlling polymer.
  • Suitable hydrophilic gel-forming polymers include, but are not necessarily limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, and polyethylene oxide.
  • use of a material with higher average molecular weight provides higher viscosity in aqueous solution of any given concentration; hence use of a higher molecular weight generally enables use of a lesser quantity of polymer to achieve the required retardation of dissolution.
  • the polymers used are usually those that give a viscosity of more than 100 mPa.s in 2 percent aqueous solution (20 0 C), generally more than 250 mPa.s, and preferably more than 500 mPa.s.
  • Preferred hydrophilic gel-forming polymers are selected from hydropropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and polyethylene oxide. Especially preferred is hydroxypropyl methylcellulose having 18-29% methoxyl substitution and 7-10% hydroxypropyl substitution, and having a number average molecular weight of at least 20,000 g/mol.
  • Such polymers include those sold by Colorcon under the tradenames Methocel ® K4M, Methocel ® K15M, Methocel ® K100M and Polyox ® WSR.
  • hydrophilic matrix agents which can be used according to the present invention are: noncellulose polysaccharides (galactomannans, guar gum, carob gum, gum arabic, sterculia gum, agar, pregelatinized starch, alginates and the like); polyvinylpyrrolidone; polyvinylacetate; acrylic acid polymers, such as crosslinked acrylic acid-based polymers; and a mixture of two or more of the said agents.
  • the hydrophilic matrix agents may be present in the form of a single compound or in the form of a mixture of compounds.
  • the hydrophilic matrix agents preferably used according to the present invention are hydroxypropyl methylcelluloses, such as Methocel ® K, or polyethylene oxide, such as Polyox ® WSR.
  • the pharmaceutical composition according to the present invention comprises 5 to 80 % per weight of hydrophilic matrix agent with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition according to the present invention comprises 10 to 75 % per weight of hydrophilic matrix agent.
  • the pharmaceutical composition according to the present invention comprises 15 to 70 % per weight of hydrophilic matrix agent; more preferably 20.0 to 65 % per weight of hydrophilic matrix agent; and most preferably 20.0 to 60 % per weight of hydrophilic matrix agent with respect to the total weight of the core of the tablet.
  • the specific surface area of the core tablet is comprised between 2 mnr1 and 0.3 mm "' ' . Preferably it is comprised between 1 .7 and 0.5 mnr1 . More preferably, it is comprised between 1 .3 and 0.6 mm “1 .
  • the "Surface Area” is understood to be the ratio between the surface of the core tablet and the volume of the core tablet.
  • the pharmaceutical composition of the invention may also comprise processing aids such as a gliding agent, lubricant, diluent, and binders, as excipient within the core of the tablets.
  • processing aids such as a gliding agent, lubricant, diluent, and binders, as excipient within the core of the tablets.
  • gliding agent as used herein is defined as an agent improving the fluidity of the powder and thus the filling of the granulation machine and the tablet press.
  • the gliding agent may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds.
  • examples of gliding agents are, but not limited to, talc, starches, stearic acid and anhydrous colloidal silica.
  • Preferred gliding agent according to the present invention is anhydrous colloidal silica, such as Aerosil 200 ® .
  • the pharmaceutical composition according to the present invention comprises 0.0 to 3.0 % per weight of gliding agent.
  • the pharmaceutical composition according to the present invention comprises 0.0 to 1 .5 % per weight of gliding agent.
  • the pharmaceutical composition of the invention may also comprise a lubricant, as excipient within the core of the tablet
  • lubricant as used herein is defined as an agent able to decrease adhesion of a powder to punches and friction between particles.
  • the lubricant may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds.
  • lubricants are, but not limited to, talc, magnesium stearate, calcium stearate, poloxamer, sodium lauryl sulfate, stearic acid or macrogol (also referred to as polyethylene glycol or PEG).
  • Preferred lubricant according to the present invention is magnesium stearate and macrogol 6000.
  • the number "6000" after polyethylene glycol refers to the average molecular weight of the polyethylene glycol.
  • the pharmaceutical composition according to the present invention comprises 0.0 to 5.50 % per weight of lubricant with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition according to the present invention comprises 0.0 to 3.50 % per weight of lubricant with respect to the total weight of the core of the tablet. More preferably, the pharmaceutical composition according to the present invention comprises 0.5 to 2.0 % per weight of lubricant with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition of the invention may also comprise diluents as excipient within the core of the tablet
  • diluent as used herein is defined as an agent used as filler in order to achieve the desired tablet volume or weight.
  • the diluent may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds. If the properties of the diluent are enough, it could also play a functional role in the formulation and one could get rid of one or several other specific processing aid excipients.
  • diluent examples include, but not limited to, lactose, starch, pregelatinized starch, microcrystalline cellulose, silicified microcystalline cellulose, cellulose acetate, dextrose, mannitol, sodium phosphate, potassium phosphate, calcium phosphate, fructose, maltose, sorbitol, or sucrose.
  • Preferred diluant are microcrystalline cellulose, lactose and starch.
  • the pharmaceutical composition according to the present invention comprises 0.0 to 75 % per weight of diluent with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition according to the present invention comprises 0 to 60 % per weight of diluent with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition according to the present invention comprises 0 to 40 % per weight of diluent with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition of the invention may also comprise binders as excipient within the core of the tablet.
  • binder as used herein is defined as an agent used to increase the cohesion of the granules during the compression, in order to obtain tablets with a defined hardness, or to act as processing aid during a granulation process.
  • the binder may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds.
  • binder When the binder is a water soluble polymer, usually it shows viscosity values lower than 500 mPa.s in 2 percent aqueous solution.
  • water soluble binders show viscosity values lower than 100 mPa.s in 2 percent aqueous solution (20 0 C).
  • examples of binders are, but not limited to, starch, microcrystalline cellulose, silicified microcystalline cellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, sucrose, dextrin, maltodextrin, sorbitol, polyvinylpirrolidone (PVP), methylcellulose, pregelatinized starch.
  • Prefered binders are microcystalline cellulose for direct compression or dry granulation tablets, and pregelatinized starch, hydroxypropylmethyl cellulose and polyvinylpirrolidone for wet granulation tablets.
  • the pharmaceutical composition according to the present invention comprises 0.0 to 80 % per weight of binder with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition according to the present invention comprises 1 to 70 % per weight of binder with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition according to the present invention comprises 2 to 60 % per weight of binder with respect to the total weight of the core of the tablet.
  • the pharmaceutical composition comprises Brivaracetam as active ingredient and 5.0 to 80.0 % of hydrophilic matrix agent, 0.0 to 75% of diluent, 0.0 to 80% of binder, 0.0 to 3.0 % of gliding agent, and 0.0 to 5.50 % of lubricant, with respect to the total weight of the core of the tablet.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and 10.0 to 75.0 % of hydrophilic matrix agent, 0.0 to 60% of diluent,
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and 15.0 to 70 % of hydrophilic matrix agent, 0.0 to 40% of diluent, 2.0to 60% of binder, 0.0 to 2.0 % of gliding agent, and
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and 10 to 75 % of hydroxypropylmethylcellulose,
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • magnesium stearate 0.4 to 1 .3 % of magnesium stearate, with respect to the total weight of the core of the tablet.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • magnesium stearate 0.0 to 5.5 % of magnesium stearate, with respect to the total weight of the core of the tablet.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • magnesium stearate 0.0 to 3.5 % of magnesium stearate, with respect to the total weight of the core of the tablet.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • hydroxypropylmethylcellulose 25 to 60 % of hydroxypropylmethylcellulose, 0 to 2% of polyvinylpyrolidone, 0.0 to 20 % of lactose, 2.0 to 60% of microcrystalline cellulose, 0.0 to 2.0 % of anhydrous colloidal silica, and 0.4 to 1 .3 % of magnesium stearate, with respect to the total weight of the core of the tablet.
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam as active ingredient and
  • the pharmaceutical composition of the invention can be manufactured by any process according to conventional methods known by the man skilled in the art. Examples of processes are direct compression, dry granulation, wet granulation, melt granulation.
  • the active ingredient could either be placed within the internal phase as a solid material, in the external phase as a solid material, be dissolved in the liquid phase or a mix of thereof.
  • the hydrophilic agents could either be incorporated in the liquid phase, in the internal phase, as solid materials, or in the external phase, or a mix of thereof.
  • tablets are produced by compressing a mix of granules (the internal phase) and other excipients (the external phase).
  • the granules are prepared through a wet granulation process, by dissolving Brivaracetam into a water solution and by spraying it into a powder bed.
  • the weight ratio between the powder bed and water ranges from 1 .0 to 10.0, the weight ratio between the powder bed and
  • Brivaracetam ranges from 1 .0 to 20.0 and the Brivaracetam concentration in the solution ranges from 5% to 45% (in weight %).
  • the weight ratio between the powder bed and water ranges from 1 .0 to 5.0, the weight ratio between the powder bed and
  • Brivaracetam ranges from 2.0 to 10.0 and the Brivaracetam concentration in the solution ranges from 15% to 40% (in weight %). More particularly, in a specific embodiment, the weight ratio between the powder bed and water ranges from 1 .2 to 2.5, the weight ratio between the powder bed and Brivaracetam ranges from 2.5 to 5.0. and the Brivaracetam concentration in the solution ranges from 20% to 35% (in weight %).
  • wet granulation process was found to bring an unexpected positive effect on the drug dissolution, when compared to direct compression process. This unexpected phenomenon could be explained by a synergetic effect of microcrystalline cellulose and hydroxypropylmethylcellulose, as
  • Brivaracetam is finely dispersed and/or entrapped in the internal phase. Consequently, smaller pores are created by the dissolution of the active pharmaceutical ingredient, and it has also to diffuse out of the microcrystalline granules. Hence, the dissolution of
  • the invention relates to a solid pharmaceutical composition
  • a solid pharmaceutical composition comprising granules and an external phase, said granules containing brivaracetam, as active ingredient, and said external phase containing 5% to 80% per weight of at least one hydrophilic matrix agent, with respect to the total weight of the core of the tablet.
  • the granule comprises at least a diluent, excipient as defined above.
  • the external phase comprises at least a lubricant, excipient as defined above.
  • the external phase may also comprise at least a gliding agent, excipient as defined above.
  • the external phase may comprise at least a diluent, excipient as defined above.
  • the process may comprise a further coating step in which a solvent, preferably purified water, is added to the coating agent and resulting suspension is sprayed on the core of the tablet.
  • a solvent preferably purified water
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising Brivaracetam useful for the treatment or prevention of a disease.
  • disease we understand a disease selected from the group consisiting of epileptogenesis, seizure disorders, convulsions, Parkinson's disease, dyskinesia induced by dopamine replacement therapy, tardive dyskinesia induced by administration of neuroleptic drugs, Huntington Chorea, and other neurological disorders including bipolar disorders, mania, depression, anxiety, attention deficit hyperactivity disorder (ADHD), migraine, cluster headache, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine and other substance abuse (e.g.
  • ADHD attention deficit hyperactivity disorder
  • benzodiazepines opiates, marijuana, barbiturates, amphetamines, other stimulants
  • stroke myoclonus, dystonia, dyskinesia, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis.
  • treatment includes curative treatment and prophylactic treatment.
  • curative is meant efficacy in treating a current symptomatic episode of a disorder or condition.
  • prophylactic is meant prevention of the occurrence or recurrence of a disorder or condition.
  • the present invention concerns also a method for treatment of a human patient by using the pharmaceutical composition.
  • the present invention concerns also the pharmaceutical composition for use as a medicament for curing the said disease.
  • the present invention concerns also the use of the pharmaceutical composition for the manufacture of a medicament for a therapeutic application in the said disease.
  • said disease is selected from the group consisting essentially of epilepsy, Parkinson's disease, dyskinesia, migraine, tremor, essential tremor, bipolar disorders, chronic pain, neuropathic pain, or bronchial, asthmatic or allergic conditions. More preferably said disease is epilepsy.
  • the present invention concerns also a method for manufacturing a medicament intended for therapeutic application in the said disease, characterized in that the pharmaceutical composition according to the present invention is used.
  • the present invention is also directed to methods of treating humans to alleviate disease by the administration of the pharmaceutical composition.
  • the following examples are provided for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate that routine variations and modifications of the following examples can be made without exceeding the spirit or scope of the invention. Examples
  • 300 mg round convex tablets A, B, and C are prepared by direct compression process according to the invention with the following core compositions (Table 1 ). Table 1 . Core compositions of tablets A, B and C.
  • Aerosil ® 200 1 .5 0.5 1 .5 0.5 1 .5 0.5
  • Hydropropyl methylcellulose sold under the trademark Methocel ® is used as a hydrophilic matrix agent.
  • the compound Methocel ® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer.
  • the viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel ® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer.
  • Lactose is sold under the trademark Tablettose ® 80; it is used as filler.
  • Microcrystalline cellulose is sold under the trademark Avicel ® PH102. It is used as tablet binder.
  • Anhydrous colloidal silica is sold under the trademark Aerosil ® 200. it is used as gliding agent.
  • Magnesium stearate is used as a lubricant.
  • Tablets A, B and C show a sustained release of the Brivaracetam what comply with the in vitro dissolution requirements.
  • Table 2 results in %
  • the in vitro dissolution profiles in water of tablets A, B and C were determined according to the USP ⁇ 71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h.
  • the dissolution was conducted at 37 0 C in a pH 6.4 phosphate buffer.
  • 300 mg round convex tablets D are prepared by direct compression process according to the invention with the following core compositions (Table 3). Table 3. Core compositions of tablets D Ingredients Tablet D mg %
  • Polyox ® WSR 303 is a brand name for a high molecular weight polyethylene oxide that is used as a hydrophilic matrix agent.
  • the viscosity of an aqueous solution in water for 1 % (w/w) of the compound Polyox ® WSR 303 is about 10000 mPa.s.
  • Lactose is sold under the trademark Tablettose ® 80; it is used as filler.
  • Microcrystalline cellulose is sold under the trademark Avicel ® PH102. It is used as tablet binder.
  • Anhydrous colloidal silica is sold under the trademark Aerosil ® 200. it is used as gliding agent.
  • Magnesium stearate is used as a lubricant.
  • Tablets D show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
  • Example 3 500 mg round Tablets E and F are prepared by a wet granulation process according to the invention with the following core compositions (Table 5).
  • Brivaracetam is dissolved in purified water and sprayed up to the appropriate dose onto a powder bed.
  • Hydropropyl methylcellulose sold under the trademark Methocel ® is used as a hydrophilic matrix agent.
  • the compound Methocel ® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer.
  • the viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel ® K 15M CRP is about
  • the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer.
  • Microcrystalline cellulose is sold under the trademark Avicel ® PH1 12. It is used as tablet binder. Lactose 100 mesh is used as a filler
  • Anhydrous colloidal silica is sold under the trademark Aerosil 200. it is used as gliding agent.
  • Povidone ® K30 polyvinylpyrrolidone, PVP
  • Lycatab® C pregelatinized maize starch
  • 352 mg round Tablets G are prepared by a wet granulation process according to the invention with the following core compositions (Table 7).
  • the obtained granules are subsequently dried, milled and mixed with the external phase.
  • the granules are compressed into tablets.
  • Hydropropyl methylcellulose sold under the trademark Methocel ® is used as a hydrophilic matrix agent.
  • the compound Methocel ® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer.
  • the viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel ® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer.
  • Microcrystalline cellulose is sold under the trademark Avicel ® PH102. It is used as tablet binder.
  • Tablettose ® 80 is a monohydrate lactose used as a filler.
  • Anhydrous colloidal silica is sold under the trademark Aerosil ® 200. it is used as gliding agent.
  • Tablets G show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
  • Table 8 results in %
  • the in vitro dissolution profiles in water of tablets G are determined according to the USP ⁇ 71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h.
  • the dissolution was conducted at 37 0 C in a pH 6.4 phosphate buffer.
  • Hydropropyl methylcellulose sold under the trademark Methocel ® is used as a hydrophilic matrix agent.
  • the compound Methocel ® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer.
  • the viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel ® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer.
  • Microcrystalline cellulose is sold under the trademark Avicel ® PH102. It is used as tablet binder.
  • Spray dried lactose is used as a filler.
  • Anhydrous colloidal silica is sold under the trademark Aerosil ® 200. it is used as gliding agent. Tablets H show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
  • the in vitro dissolution profiles in water of tablets H are determined according to the USP ⁇ 71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h.
  • the dissolution is conducted at 37 0 C in a pH 6.4 phosphate buffer.
  • the wet granulation process and formulation used for Tablets G & H gives tablets with a final weight similar to Tablets B.
  • the required level of hydrophilic polymer, required to achieve a given dissolution profile is about 50% lower for formulation G and H, than that required for formulation B.
  • the wet granulation process is found to bring an unexpected positive effect on the drug dissolution, when compared to direct compression process.
  • tablet G and H the level of hydrophilic polymer could be decreased by ca. 50% when compared to Example 1 , Tablet B, while keeping an equivalent in vitro dissolution profile.
  • This unexpected phenomenon could be explained by a synergistic effect of microcrystalline cellulose and hydroxypropylmethylcellulose, as Brivaracetam is finely dispersed and/or entrapped in the internal phase. Consequently, smaller pores are created by the dissolution of the active pharmaceutical ingredient, and it has also to diffuse out of the microcrystalline granules. Hence, the dissolution of Brivaracetam is further slowed down.
  • Example 6 720 mg round Tablets I are prepared by a wet granulation process according to the invention with the following core compositions (Table 1 1 ).
  • Hydropropyl methylcellulose sold under the trademark Methocel ® is used as a hydrophilic matrix agent.
  • the compound Methocel ® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer.
  • the viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel ® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer.
  • Microcrystalline cellulose is sold under the trademark Avicel ® PH102. It is used as tablet binder.
  • Spray dried lactose is used as a filler.
  • Anhydrous colloidal silica is sold under the trademark Aerosil ® 200. it is used as gliding agent. Tablets I show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
  • the in vitro dissolution profiles in water of tablets I are determined according to the USP ⁇ 71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h.
  • the dissolution is conducted at 37 0 C in a pH 6.4 phosphate buffer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a pharmaceutical composition comprising brivaracetam as active ingredient, the invention relates specifically to a prolonged release formulation.

Description

Pharmaceutical Compositions Comprising Brivaracetam
The present invention relates to a novel pharmaceutical composition comprising Brivaracetam.
International patent application having publication number WO 01/62726 discloses 2-oxo-1 -pyrrolidine derivatives and methods for their preparation. It particularly discloses compound (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1 -yl] butanamide known under the international non propriety name of Brivaracetam.
Figure imgf000002_0001
Brivaracetam
Brivaracetam is effective in the treatment of epilepsy. Clinical trials evaluated the efficacy and safety of Brivaracetam (5, 20, 50 and 150 mg per day) in the adjunctive treatment of adult patients (16-65 years) with refractory partial onset seizures, with or without secondary generalization. One of the objectives currently sought in the development of pharmaceutical compositions which can be administered orally is to control the release of pharmaceutically active substances so that they can be administered in a few daily doses, ideally in a single daily dose.
Brivaracetam is a very water soluble active ingredient (ca. 700 mg /ml), and it is not obvious to slow down the release of the drug.
Moreover another problem consists in the reduction of the release rate, while keeping a reasonable size to the pharmaceutical form given to the patients.
Surprisingly, it was discovered that it was possible to accurately control the release rate of the drug substance so that it can be administered in a few daily doses, and even in a single daily dose and so to provide a therapeutic effect for at least 16 hours when administered to a patient.
Considering Brivaracetam is classified as BCS I, the resulting in vitro dissolution (USP <71 1 > apparatus n °2) in a bufferred aqueous media has to show a drug release of no more than 40% after 1 hour of dissolution, of 35% - 80% after 4 hours of dissolution and of no less than 80% after 16 hours of dissolution. Preferably, a profile of no more than 35% after 1 hour of dissolution, of 40% - 75% after 4 hours of dissolution and of no less than 80% after 16 hours of dissolution. More preferably a profile of no more than 30% after 1 hour of dissolution, of 45% - 70% after 4 hours of dissolution and of no less than 80% after 16 hours of dissolution.
The present invention relates to a pharmaceutical composition in the form of a tablet comprising, as active ingredient, Brivaracetam and, as excipient within the core of the tablet, 5% to 80% per weight of at least one hydrophilic matrix agent, with respect to the total weight of the core of the tablet.
The term "active ingredient" as used herein is defined as a substance which has a therapeutic effect. The amount of the active ingredient present in the pharmaceutical composition of the invention may vary depending on the patient to which the compositions are administered and on the specific disease to be treated.
The term "core of the tablet" as used herein is defined as the pharmaceutical composition without coating. All the percentages are given per weight of the total weight of the core of the tablet, except when it is written otherwise.
The term "hydrophilic matrix agent" as used herein is defined as a pharmaceutical acceptable excipient which generates a gel in contact to water. A "hydrophilic matrix agent" is a material that is a water dispersible rate controlling polymer. Suitable hydrophilic gel-forming polymers include, but are not necessarily limited to, hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, and polyethylene oxide. For any given polymer type, use of a material with higher average molecular weight provides higher viscosity in aqueous solution of any given concentration; hence use of a higher molecular weight generally enables use of a lesser quantity of polymer to achieve the required retardation of dissolution. The polymers used are usually those that give a viscosity of more than 100 mPa.s in 2 percent aqueous solution (20 0C), generally more than 250 mPa.s, and preferably more than 500 mPa.s. Preferred hydrophilic gel-forming polymers are selected from hydropropyl methylcellulose, hydroxypropyl cellulose, hydroxyethyl cellulose and polyethylene oxide. Especially preferred is hydroxypropyl methylcellulose having 18-29% methoxyl substitution and 7-10% hydroxypropyl substitution, and having a number average molecular weight of at least 20,000 g/mol. Such polymers include those sold by Colorcon under the tradenames Methocel® K4M, Methocel® K15M, Methocel® K100M and Polyox® WSR. Other examples of hydrophilic matrix agents which can be used according to the present invention are: noncellulose polysaccharides (galactomannans, guar gum, carob gum, gum arabic, sterculia gum, agar, pregelatinized starch, alginates and the like); polyvinylpyrrolidone; polyvinylacetate; acrylic acid polymers, such as crosslinked acrylic acid-based polymers; and a mixture of two or more of the said agents. The hydrophilic matrix agents may be present in the form of a single compound or in the form of a mixture of compounds. The hydrophilic matrix agents preferably used according to the present invention are hydroxypropyl methylcelluloses, such as Methocel® K, or polyethylene oxide, such as Polyox® WSR.
Usually, the pharmaceutical composition according to the present invention comprises 5 to 80 % per weight of hydrophilic matrix agent with respect to the total weight of the core of the tablet.
Particularly, the pharmaceutical composition according to the present invention comprises 10 to 75 % per weight of hydrophilic matrix agent.
Preferably, the pharmaceutical composition according to the present invention comprises 15 to 70 % per weight of hydrophilic matrix agent; more preferably 20.0 to 65 % per weight of hydrophilic matrix agent; and most preferably 20.0 to 60 % per weight of hydrophilic matrix agent with respect to the total weight of the core of the tablet.
Usually the specific surface area of the core tablet is comprised between 2 mnr1 and 0.3 mm"'' . Preferably it is comprised between 1 .7 and 0.5 mnr1 . More preferably, it is comprised between 1 .3 and 0.6 mm"1 . The "Surface Area" is understood to be the ratio between the surface of the core tablet and the volume of the core tablet.
The pharmaceutical composition of the invention may also comprise processing aids such as a gliding agent, lubricant, diluent, and binders, as excipient within the core of the tablets.
The term "gliding agent" as used herein is defined as an agent improving the fluidity of the powder and thus the filling of the granulation machine and the tablet press. The gliding agent may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds. Examples of gliding agents are, but not limited to, talc, starches, stearic acid and anhydrous colloidal silica. Preferred gliding agent according to the present invention is anhydrous colloidal silica, such as Aerosil 200®.
Usually, the pharmaceutical composition according to the present invention comprises 0.0 to 3.0 % per weight of gliding agent. Preferably, the pharmaceutical composition according to the present invention comprises 0.0 to 1 .5 % per weight of gliding agent. The pharmaceutical composition of the invention may also comprise a lubricant, as excipient within the core of the tablet
The term "lubricant" as used herein is defined as an agent able to decrease adhesion of a powder to punches and friction between particles. The lubricant may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds.
Examples of lubricants are, but not limited to, talc, magnesium stearate, calcium stearate, poloxamer, sodium lauryl sulfate, stearic acid or macrogol (also referred to as polyethylene glycol or PEG). Preferred lubricant according to the present invention is magnesium stearate and macrogol 6000.
As will be understood by the person skilled in the art, the number "6000" after polyethylene glycol refers to the average molecular weight of the polyethylene glycol.
Usually, the pharmaceutical composition according to the present invention comprises 0.0 to 5.50 % per weight of lubricant with respect to the total weight of the core of the tablet.
Preferably, the pharmaceutical composition according to the present invention comprises 0.0 to 3.50 % per weight of lubricant with respect to the total weight of the core of the tablet. More preferably, the pharmaceutical composition according to the present invention comprises 0.5 to 2.0 % per weight of lubricant with respect to the total weight of the core of the tablet.
The pharmaceutical composition of the invention may also comprise diluents as excipient within the core of the tablet The term "diluent" as used herein is defined as an agent used as filler in order to achieve the desired tablet volume or weight. The diluent may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds. If the properties of the diluent are enough, it could also play a functional role in the formulation and one could get rid of one or several other specific processing aid excipients.
Examples of diluent are, but not limited to, lactose, starch, pregelatinized starch, microcrystalline cellulose, silicified microcystalline cellulose, cellulose acetate, dextrose, mannitol, sodium phosphate, potassium phosphate, calcium phosphate, fructose, maltose, sorbitol, or sucrose. Preferred diluant are microcrystalline cellulose, lactose and starch. Usually, the pharmaceutical composition according to the present invention comprises 0.0 to 75 % per weight of diluent with respect to the total weight of the core of the tablet.
Preferably, the pharmaceutical composition according to the present invention comprises 0 to 60 % per weight of diluent with respect to the total weight of the core of the tablet.
More preferably, the pharmaceutical composition according to the present invention comprises 0 to 40 % per weight of diluent with respect to the total weight of the core of the tablet. The pharmaceutical composition of the invention may also comprise binders as excipient within the core of the tablet.
The term "binder" as used herein is defined as an agent used to increase the cohesion of the granules during the compression, in order to obtain tablets with a defined hardness, or to act as processing aid during a granulation process. The binder may be present in the pharmaceutical composition in the form of a single compound or in the form of a mixture of compounds.
When the binder is a water soluble polymer, usually it shows viscosity values lower than 500 mPa.s in 2 percent aqueous solution. Preferably, water soluble binders show viscosity values lower than 100 mPa.s in 2 percent aqueous solution (20 0C). Examples of binders are, but not limited to, starch, microcrystalline cellulose, silicified microcystalline cellulose, carboxymethylcellulose, hydroxypropyl methylcellulose, sucrose, dextrin, maltodextrin, sorbitol, polyvinylpirrolidone (PVP), methylcellulose, pregelatinized starch.
Prefered binders are microcystalline cellulose for direct compression or dry granulation tablets, and pregelatinized starch, hydroxypropylmethyl cellulose and polyvinylpirrolidone for wet granulation tablets.
Usually, the pharmaceutical composition according to the present invention comprises 0.0 to 80 % per weight of binder with respect to the total weight of the core of the tablet. Preferably, the pharmaceutical composition according to the present invention comprises 1 to 70 % per weight of binder with respect to the total weight of the core of the tablet.
More preferably, the pharmaceutical composition according to the present invention comprises 2 to 60 % per weight of binder with respect to the total weight of the core of the tablet.
In one embodiment of the invention, the pharmaceutical composition comprises Brivaracetam as active ingredient and 5.0 to 80.0 % of hydrophilic matrix agent, 0.0 to 75% of diluent, 0.0 to 80% of binder, 0.0 to 3.0 % of gliding agent, and 0.0 to 5.50 % of lubricant, with respect to the total weight of the core of the tablet.
Particularly, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and 10.0 to 75.0 % of hydrophilic matrix agent, 0.0 to 60% of diluent,
1 .0 to 70% of binder, 0.0 to 2.5 % of gliding agent, and 0.0 to 3.5 % of lubricant, with respect to the total weight of the core of the tablet. Preferably, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and 15.0 to 70 % of hydrophilic matrix agent, 0.0 to 40% of diluent, 2.0to 60% of binder, 0.0 to 2.0 % of gliding agent, and
0.4 to 1 .3 % of lubricant, with respect to the total weight of the core of the tablet.
In a particular embodiment for direct compression tablet, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
5.0 to 80 % of hydroxypropylmethylcellulose, 0.0 to 75% of lactose, 0.0 to 80% of microcrystalline cellulose, 0.0 to 3.0 % of anhydrous colloidal silica, and 0.0 to 5.5 % of magnesium stearate, with respect to the total weight of the core of the tablet.
Usually, in a particular embodiment for direct compression tablet, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and 10 to 75 % of hydroxypropylmethylcellulose,
0.0 to 60% of lactose, 1 .0 to 70% of microcrystaline cellulose, 0.0 to 2.5 % of anhydrous colloidal silica, and 0.0 to 3.5 % of magnesium stearate, with respect to the total weight of the core of the tablet.
Particularly, in a particular embodiment for direct compression tablet, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
25 to 60 % of hydroxypropylmethylcellulose, 0.0 to 40% of lactose, 2.0 to 60% of microcrystalline cellulose, 0.0 to 2.0 % of anhydrous colloidal silica, and
0.4 to 1 .3 % of magnesium stearate, with respect to the total weight of the core of the tablet.
In a particular embodiment for wet granulation tablets, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
5.0 to 80 % of hydroxypropylmethylcellulose, 0 to 5% of polyvinylpyrolidone, 0.0 to 80 % of microcrystalline cellulose, 0.0 to 40 % of lactose, 0.0 to 3.0 % of anhydrous colloidal silica, and
0.0 to 5.5 % of magnesium stearate, with respect to the total weight of the core of the tablet.
Usually, in a particular embodiment for wet granulation tablet, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
10 to 75 % of hydroxypropylmethylcellulose, 0 to 3% of polyvinylpyrolidone, 0.0 to 30 % of lactose, 1 .0 to 70% of microcrystaline cellulose, 0.0 to 2.5 % of anhydrous colloidal silica, and
0.0 to 3.5 % of magnesium stearate, with respect to the total weight of the core of the tablet.
Particularly, in a particular embodiment for wet granulation tablet, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
25 to 60 % of hydroxypropylmethylcellulose, 0 to 2% of polyvinylpyrolidone, 0.0 to 20 % of lactose, 2.0 to 60% of microcrystalline cellulose, 0.0 to 2.0 % of anhydrous colloidal silica, and 0.4 to 1 .3 % of magnesium stearate, with respect to the total weight of the core of the tablet.
In another particular embodiment for wet granulation tablets, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
5.0 to 80 % of hydroxypropylmethylcellulose, 0.0 to 80% of microcrystalline cellulose,
0.0 to 75% of lactose, 0.0 to 40% of pregelatinized maize starch, 0.0 to 3.0 % of anhydrous colloidal silica, and 0.0 to 5.5 % of magnesium stearate, with respect to the total weight of the core of the tablet.
Usually, in a particular embodiment for wet granulation tablet, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
10 to 75 % of hydroxypropylmethylcellulose, 1 .0 to 70% of microcrystaline cellulose,
0.0 to 60% of lactose, 0.0 to 30% of pregelatinized maize starch, 0.0 to 2.5 % per weight of anhydrous colloidal silica, and 0.0 to 3.5 % per weight of magnesium stearate, with respect to the total weight of the core of the tablet.
Particularly, in a particular embodiment for wet granulation tablet, the present invention relates to a pharmaceutical composition comprising Brivaracetam as active ingredient and
25 to 60 % of hydroxypropylmethylcellulose, 2.0 to 60% of microcrystalline cellulose,
0.0 to 40% of lactose, 0.0 to 20% of pregelatinized maize starch, 0.0 to 2.0 % of anhydrous colloidal silica, and 0.4 to 1 .3 % of magnesium stearate, with respect to the total weight of the core of the tablet.
The pharmaceutical composition of the invention can be manufactured by any process according to conventional methods known by the man skilled in the art. Examples of processes are direct compression, dry granulation, wet granulation, melt granulation.
For wet granulation processes, the active ingredient could either be placed within the internal phase as a solid material, in the external phase as a solid material, be dissolved in the liquid phase or a mix of thereof. The hydrophilic agents could either be incorporated in the liquid phase, in the internal phase, as solid materials, or in the external phase, or a mix of thereof.
In a specific embodiment of the invention, tablets are produced by compressing a mix of granules (the internal phase) and other excipients (the external phase). The granules are prepared through a wet granulation process, by dissolving Brivaracetam into a water solution and by spraying it into a powder bed.
Usually, in a specific embodiment, the weight ratio between the powder bed and water ranges from 1 .0 to 10.0, the weight ratio between the powder bed and
Brivaracetam ranges from 1 .0 to 20.0 and the Brivaracetam concentration in the solution ranges from 5% to 45% (in weight %).
Particularly, in a specific embodiment, the weight ratio between the powder bed and water ranges from 1 .0 to 5.0, the weight ratio between the powder bed and
Brivaracetam ranges from 2.0 to 10.0 and the Brivaracetam concentration in the solution ranges from 15% to 40% (in weight %). More particularly, in a specific embodiment, the weight ratio between the powder bed and water ranges from 1 .2 to 2.5, the weight ratio between the powder bed and Brivaracetam ranges from 2.5 to 5.0. and the Brivaracetam concentration in the solution ranges from 20% to 35% (in weight %).
In a specific embodiment of the invention, wet granulation process was found to bring an unexpected positive effect on the drug dissolution, when compared to direct compression process. This unexpected phenomenon could be explained by a synergetic effect of microcrystalline cellulose and hydroxypropylmethylcellulose, as
Brivaracetam is finely dispersed and/or entrapped in the internal phase. Consequently, smaller pores are created by the dissolution of the active pharmaceutical ingredient, and it has also to diffuse out of the microcrystalline granules. Hence, the dissolution of
Brivaracetam is further slowed down.
So, the invention relates to a solid pharmaceutical composition comprising granules and an external phase, said granules containing brivaracetam, as active ingredient, and said external phase containing 5% to 80% per weight of at least one hydrophilic matrix agent, with respect to the total weight of the core of the tablet. Usually, the granule comprises at least a diluent, excipient as defined above. Usually, the external phase comprises at least a lubricant, excipient as defined above. Usually, the external phase may also comprise at least a gliding agent, excipient as defined above. Usually, the external phase may comprise at least a diluent, excipient as defined above.
The process may comprise a further coating step in which a solvent, preferably purified water, is added to the coating agent and resulting suspension is sprayed on the core of the tablet.
In another aspect the present invention relates to a pharmaceutical composition comprising Brivaracetam useful for the treatment or prevention of a disease.
By the term "disease", we understand a disease selected from the group consisiting of epileptogenesis, seizure disorders, convulsions, Parkinson's disease, dyskinesia induced by dopamine replacement therapy, tardive dyskinesia induced by administration of neuroleptic drugs, Huntington Chorea, and other neurological disorders including bipolar disorders, mania, depression, anxiety, attention deficit hyperactivity disorder (ADHD), migraine, cluster headache, trigeminal and other neuralgia, chronic pain, neuropathic pain, cerebral ischemia, cardiac arrhythmia, myotonia, cocaine and other substance abuse (e.g. alcohol, benzodiazepines, opiates, marijuana, barbiturates, amphetamines, other stimulants), stroke, myoclonus, dystonia, dyskinesia, tremor, essential tremor, simple or complex tics, Tourette syndrome, restless leg syndrome and other movement disorders, neonatal cerebral haemorrhage, amyotrophic lateral sclerosis, spasticity and degenerative diseases, bronchial asthma, asthmatic status and allergic bronchitis, asthmatic syndrome, bronchial hyperreactivity and bronchospastic syndromes as well as allergic and vasomotor rhinitis and rhinoconjunctivitis.
The term "treatment" as used herein, includes curative treatment and prophylactic treatment.
By "curative" is meant efficacy in treating a current symptomatic episode of a disorder or condition. By "prophylactic" is meant prevention of the occurrence or recurrence of a disorder or condition.
The present invention concerns also a method for treatment of a human patient by using the pharmaceutical composition.
The present invention concerns also the pharmaceutical composition for use as a medicament for curing the said disease.
The present invention concerns also the use of the pharmaceutical composition for the manufacture of a medicament for a therapeutic application in the said disease. Preferably said disease is selected from the group consisting essentially of epilepsy, Parkinson's disease, dyskinesia, migraine, tremor, essential tremor, bipolar disorders, chronic pain, neuropathic pain, or bronchial, asthmatic or allergic conditions. More preferably said disease is epilepsy. The present invention concerns also a method for manufacturing a medicament intended for therapeutic application in the said disease, characterized in that the pharmaceutical composition according to the present invention is used.
The present invention is also directed to methods of treating humans to alleviate disease by the administration of the pharmaceutical composition. The following examples are provided for illustrative purposes only and are not intended, nor should they be construed, as limiting the invention in any manner. Those skilled in the art will appreciate that routine variations and modifications of the following examples can be made without exceeding the spirit or scope of the invention. Examples
Example 1
300 mg round convex tablets A, B, and C are prepared by direct compression process according to the invention with the following core compositions (Table 1 ). Table 1 . Core compositions of tablets A, B and C.
Ingredients Tablet A Tablet B Tablet C mg % mg % mg %
Brivaracetam 50 16.7 50 16.7 50 16.7
Methocel® K15 MCR 90 30 135 45 225 75
Tablettose® 80 103.7 34.6 73.7 24.6 13.7 4.6
Avicel® PH102 51.8 17.3 36.8 12.3 6.8 2.3
Aerosil® 200 1 .5 0.5 1 .5 0.5 1 .5 0.5
Magnesium stearate 3 1 3 1 3 1
Tablet diameter (mm) 9 9 9
Specific Surface area (mm 1) 0.9 0.9 0.9
Hydropropyl methylcellulose sold under the trademark Methocel®is used as a hydrophilic matrix agent. The compound Methocel® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer. The viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer.
Lactose is sold under the trademark Tablettose® 80; it is used as filler.
Microcrystalline cellulose is sold under the trademark Avicel® PH102. It is used as tablet binder.
Anhydrous colloidal silica is sold under the trademark Aerosil® 200. it is used as gliding agent.
Magnesium stearate is used as a lubricant.
Tablets A, B and C show a sustained release of the Brivaracetam what comply with the in vitro dissolution requirements. Table 2: results in %
Figure imgf000013_0001
The in vitro dissolution profiles in water of tablets A, B and C were determined according to the USP <71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h. The dissolution was conducted at 370C in a pH 6.4 phosphate buffer.
Example 2
300 mg round convex tablets D are prepared by direct compression process according to the invention with the following core compositions (Table 3). Table 3. Core compositions of tablets D Ingredients Tablet D mg %
Brivaracetam 50 16.7
Polyox® WSR 303 135 45
Tablettose® 80 73.7 24.6
Avicel® PH102 38.6 12.3
Aerosil ® 200 1 .5 0.5
Magnesium stearate 3 1
Tablet diameter (mm) 9 Specific Surface area (mm"1 ) 0.9 Polyox® WSR 303 is a brand name for a high molecular weight polyethylene oxide that is used as a hydrophilic matrix agent. The viscosity of an aqueous solution in water for 1 % (w/w) of the compound Polyox® WSR 303 is about 10000 mPa.s.
Lactose is sold under the trademark Tablettose® 80; it is used as filler.
Microcrystalline cellulose is sold under the trademark Avicel® PH102. It is used as tablet binder.
Anhydrous colloidal silica is sold under the trademark Aerosil® 200. it is used as gliding agent.
Magnesium stearate is used as a lubricant.
Tablets D show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
Table 4: results in %
Figure imgf000014_0001
The in vitro dissolution profiles in water of tablets D are determined according to the USP <71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h. The dissolution was conducted at 370C in a pH 6.4 phosphate buffer. Example 3 500 mg round Tablets E and F are prepared by a wet granulation process according to the invention with the following core compositions (Table 5).
Table 5
Figure imgf000014_0002
Figure imgf000015_0001
The manufacturing took place in 3 main steps:
1 . Brivaracetam is dissolved in purified water and sprayed up to the appropriate dose onto a powder bed.
2. The obtained granules are subsequently dried, milled and mixed with the external phase
3. The granules are compressed into tablets.
Hydropropyl methylcellulose sold under the trademark Methocel®is used as a hydrophilic matrix agent. The compound Methocel® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer. The viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel® K 15M CRP is about
15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer.
Microcrystalline cellulose is sold under the trademark Avicel® PH1 12. It is used as tablet binder. Lactose 100 mesh is used as a filler
Anhydrous colloidal silica is sold under the trademark Aerosil 200. it is used as gliding agent.
Povidone® K30 (polyvinylpyrrolidone, PVP) and Lycatab® C (pregelatinized maize starch) are binding agent Tablets E and F show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
Table 6 : results in %
Figure imgf000015_0002
The in vitro dissolution profiles in water of tablets E and F are determined according to the USP <71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 mL) over an interval of time of 16 h. The dissolution was conducted at 370C in a pH 6.4 phosphate buffer. Example 4
352 mg round Tablets G are prepared by a wet granulation process according to the invention with the following core compositions (Table 7).
Table 7 : tablet G
Figure imgf000016_0001
The manufacturing took place in 3 main steps: 1 . Brivaracetam is dissolved in purified water and sprayed up to the appropriate dose onto a powder bed.
2. The obtained granules are subsequently dried, milled and mixed with the external phase.
3. The granules are compressed into tablets. Hydropropyl methylcellulose sold under the trademark Methocel®is used as a hydrophilic matrix agent. The compound Methocel® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer. The viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer. Microcrystalline cellulose is sold under the trademark Avicel® PH102. It is used as tablet binder.
Tablettose® 80 is a monohydrate lactose used as a filler.
Anhydrous colloidal silica is sold under the trademark Aerosil® 200. it is used as gliding agent.
Tablets G show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements. Table 8 : results in %
Figure imgf000017_0001
The in vitro dissolution profiles in water of tablets G are determined according to the USP <71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h. The dissolution was conducted at 370C in a pH 6.4 phosphate buffer.
Example 5
360 mg round Tablets H are prepared by a wet granulation process according to the invention with the following core compositions (Table 9).
Table 9
Figure imgf000018_0001
The manufacturing took place in 3 main steps:
1 . Brivaracetam is dissolved in purified water and sprayed up to the appropriate dose onto a powder bed. 2. The obtained granules are subsequently dried, milled and mixed with the external phase
3. The granules are compressed into tablets.
Hydropropyl methylcellulose sold under the trademark Methocel®is used as a hydrophilic matrix agent. The compound Methocel® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer. The viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer. Microcrystalline cellulose is sold under the trademark Avicel® PH102. It is used as tablet binder.
Spray dried lactose is used as a filler.
Anhydrous colloidal silica is sold under the trademark Aerosil® 200. it is used as gliding agent. Tablets H show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
Table 10 : results in %
Time (Hours) 1 .00.00 4 .00.00 16.00.00
Tablet H 24 55 96
The in vitro dissolution profiles in water of tablets H are determined according to the USP <71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h. The dissolution is conducted at 370C in a pH 6.4 phosphate buffer. The wet granulation process and formulation used for Tablets G & H gives tablets with a final weight similar to Tablets B. Surprisingly, the required level of hydrophilic polymer, required to achieve a given dissolution profile, is about 50% lower for formulation G and H, than that required for formulation B.
The wet granulation process is found to bring an unexpected positive effect on the drug dissolution, when compared to direct compression process. As shown in examples 4 and 5, tablet G and H, the level of hydrophilic polymer could be decreased by ca. 50% when compared to Example 1 , Tablet B, while keeping an equivalent in vitro dissolution profile. This unexpected phenomenon could be explained by a synergistic effect of microcrystalline cellulose and hydroxypropylmethylcellulose, as Brivaracetam is finely dispersed and/or entrapped in the internal phase. Consequently, smaller pores are created by the dissolution of the active pharmaceutical ingredient, and it has also to diffuse out of the microcrystalline granules. Hence, the dissolution of Brivaracetam is further slowed down.
Example 6 720 mg round Tablets I are prepared by a wet granulation process according to the invention with the following core compositions (Table 1 1 ).
Table 1 1
Figure imgf000020_0001
The manufacturing took place in 3 main steps:
1 . Brivaracetam is dissolved in purified water and sprayed up to the appropriate dose onto a powder bed. 2. The obtained granules are subsequently dried, milled and mixed with the external phase
3. The granules are compressed into tablets.
Hydropropyl methylcellulose sold under the trademark Methocel®is used as a hydrophilic matrix agent. The compound Methocel® K15 M CRP (trade name) is also known as hypromellose which is a hydrophilic polymer. The viscosity of an aqueous solution in water for 2% (w/w) of the compound Methocel® K 15M CRP is about 15000 mPa.s, the grade K (methoxy and hydroxypropy content) is preferred for a better hydration rate of the polymer. Microcrystalline cellulose is sold under the trademark Avicel® PH102. It is used as tablet binder.
Spray dried lactose is used as a filler.
Anhydrous colloidal silica is sold under the trademark Aerosil® 200. it is used as gliding agent. Tablets I show a sustained release of the Brivaracetam, what comply with the in vitro dissolution requirements.
Table 12 : results in %
Time (Hours) 1 .00.00 4 .00.00 16.00.00
Tablet I 22 47 89
The in vitro dissolution profiles in water of tablets I are determined according to the USP <71 1 > (apparatus n ° 2, 50 rpm, aqueous medium 900 ml_) over an interval of time of 16 h. The dissolution is conducted at 370C in a pH 6.4 phosphate buffer.

Claims

1 . A pharmaceutical composition in the form of a tablet comprising, as active ingredient, Brivaracetam and, as excipient within the core of the tablet, 5% to 80% per weight of at least one hydrophilic matrix agent, with respect to the total weight of the core of the tablet, the hydrophilic matrix agent being a polymer having a viscosity of more than 100 mPa.s in 2 percent aqueous solution (20 0C).
2. The pharmaceutical composition according to claim 1 comprising granules and an external phase, said granules containing brivaracetam and said external phase containing at least one hydrophilic matrix agent.
3. The pharmaceutical composition according to claim 1 , comprising brivaracetam and a water dispersible, rate controlling polymer as hydrophilic matrix agent.
4. The pharmaceutical composition according to claim 1 , comprising 20 to 60 % per weight of hydrophilic matrix agent.
5. The pharmaceutical composition according to any one of claims 1 to 4 wherein the hydrophilic matrix agent is hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, sodium carboxymethylcellulose, hydroxyethylcellulose, and polyethylene oxide.
6. The pharmaceutical composition according to any one of claims 1 to 5 wherein the hydrophilic matrix agent is a hydrophilic gel-forming polymer.
7. The pharmaceutical composition according to any one of claims 1 to 6 wherein the hydrophilic matrix agent is noncellulose polysaccharide; polyvinylpyrrolidone; polyvinylacetate; acrylic acid polymer; and a mixture of two or more of the said agents.
8. The pharmaceutical composition according to any one of claims 1 to 7 wherein the specific surface area of the core tablet is comprised between 2 mm"1 and 0.3 mm"1
9. The pharmaceutical composition according to claim 1 , comprising 0.0 to 1 .5 % per weight of gliding agent with respect to the total weight of the core of the tablet.
10. The pharmaceutical composition according to claim 1 , comprising 0.5 to 2.0 % per weight of lubricant with respect to the total weight of the core of the tablet.
1 1 . The pharmaceutical composition according to claim 1 , comprising 1 to 70 % per weight of binder with respect to the total weight of the core of the tablet.
12. The pharmaceutical composition according to claim 1 1 , comprising, as binder, a water soluble polymer having viscosity values lower than 500 mPa.s in 2 percent aqueous solution.
13. The pharmaceutical composition according to claim 1 , comprising Brivaracetam as active ingredient and
5.0 to 80.0 % of hydrophilic matrix agent, 0.0 to 75% of diluent, 0.0 to 80% of binder,
0.0 to 3.0 % of gliding agent, and
0.0 to 5.5 % of lubricant, with respect to the total weight of the core of the tablet.
14. The pharmaceutical composition according to claim 1 , comprising Brivaracetam as active ingredient and
5.0 to 80 % of hydroxypropylmethylcellulose, 0.0 to 75% of lactose, 0.0 to 80% of microcrystalline cellulose, 0.0 to 3.0 % of anhydrous colloidal silica, and 0.0 to 5.5 % of magnesium stearate, with respect to the total weight of the core of the tablet; this composition being prepared by direct compression
15. The pharmaceutical composition according to claim 1 , comprising Brivaracetam as active ingredient and 5.0 to 80 % of hydroxypropylmethylcellulose,
0.0 to 80% of microcrystalline cellulose,
0.0 to 40 % of lactose,
0.0 to 5% of polyvinylpyrolidone,
0.0 to 3.0 % of anhydrous colloidal silica, and 0.0 to 5.5 % of magnesium stearate, with respect to the total weight of the core of the tablet; this composition being prepared by wet granulation.
16. The pharmaceutical composition according to claim 1 , comprising Brivaracetam as active ingredient and 5.0 to 80 % of hydroxypropylmethylcellulose,
0.0 to 80% of microcrystalline cellulose,
0.0 to 75% of lactose,
0.0 to 40% of pregelatinized maize starch,
0.0 to 3.0 % of anhydrous colloidal silica, and 0.0 to 5.5 % of magnesium stearate, with respect to the total weight of the core of the tablet; this composition being prepared by wet granulation.
PCT/EP2009/056570 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam Ceased WO2009144286A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP09753941.5A EP2285357B8 (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam
CN200980120221.XA CN102046153B (en) 2008-05-30 2009-05-28 Pharmaceutical composition comprising brivaracetam
DK09753941.5T DK2285357T3 (en) 2008-05-30 2009-05-28 Pharmaceutical composition comprising brivaracetam
JP2011511013A JP5553452B2 (en) 2008-05-30 2009-05-28 Pharmaceutical composition comprising brivaracetam
CA2722093A CA2722093C (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam
ES09753941.5T ES2465478T3 (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam
US12/993,704 US8435564B2 (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam
PL09753941T PL2285357T3 (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam
BRPI0912161A BRPI0912161A2 (en) 2008-05-30 2009-05-28 pharmaceutical composition in the form of a tablet
HK11107321.2A HK1153141B (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08009919.5 2008-05-30
EP08009919 2008-05-30

Publications (1)

Publication Number Publication Date
WO2009144286A1 true WO2009144286A1 (en) 2009-12-03

Family

ID=39714168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/056570 Ceased WO2009144286A1 (en) 2008-05-30 2009-05-28 Pharmaceutical compositions comprising brivaracetam

Country Status (10)

Country Link
US (1) US8435564B2 (en)
EP (1) EP2285357B8 (en)
JP (1) JP5553452B2 (en)
CN (1) CN102046153B (en)
BR (1) BRPI0912161A2 (en)
CA (1) CA2722093C (en)
DK (1) DK2285357T3 (en)
ES (1) ES2465478T3 (en)
PL (1) PL2285357T3 (en)
WO (1) WO2009144286A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135430A1 (en) 2010-04-29 2011-11-03 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
JP2013537238A (en) * 2010-09-21 2013-09-30 インテクリン・セラピユーテイクス・インコーポレイテツド Anti-diabetic solid pharmaceutical composition
EP3964201A4 (en) * 2020-07-09 2022-12-28 Shanghai Bocimed Pharmaceutical Co., Ltd. OPHTHALMIC PHARMACEUTICAL COMPOSITION, PROCESS FOR MANUFACTURE THEREOF AND APPLICATION THEREOF
US11911510B2 (en) 2017-08-31 2024-02-27 Purdue Pharma L.P Pharmaceutical dosage forms
EP4559456A1 (en) 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet of brivaracetam
EP4559457A1 (en) 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet composition of brivaracetam

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109069480A (en) 2015-12-30 2018-12-21 阿达玛斯医药公司 For treating the method and composition of illness relevant to epilepsy
BR112019025855A2 (en) * 2017-06-09 2020-07-14 Zoetis Broomhill Ip Limited intramammary veterinary composition
CN109833300A (en) * 2017-11-28 2019-06-04 浙江京新药业股份有限公司 A kind of antiepileptic Orally administered composition and preparation method thereof
CN110638743B (en) * 2019-10-25 2023-03-28 乐普制药科技有限公司 Composition containing brivaracetam
CN111407738A (en) * 2020-04-03 2020-07-14 江苏艾立康药业股份有限公司 Brivaracetam controlled-release preparation and preparation method thereof
US20240148693A1 (en) * 2021-03-17 2024-05-09 Changsha Jingyi Pharmaceutical Technology Co., Ltd Composition, preparation method therefor, and use thereof
CN115192572B (en) * 2021-04-08 2023-09-19 成都同道慧宜生物医药科技有限公司 Brivaracetam medicament, preparation method and application thereof
CN115721624A (en) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 Brivaracetam pharmaceutical composition, and preparation method and application thereof
US12133918B2 (en) 2021-10-01 2024-11-05 Griffin Gamma, Llc Partially pre-gelatinized cassava starch as pharmaceutical excipient
WO2023125348A1 (en) * 2021-12-27 2023-07-06 广东东阳光药业有限公司 Brivaracetam tablet and preparation method therefor
CN118416004A (en) 2023-02-02 2024-08-02 泰州越洋医药开发有限公司 A brivaracetam dual-release three-layer tablet and preparation method thereof
EP4491176A1 (en) * 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. A film coated tablet comprising brivaracetam
EP4491177A1 (en) * 2023-07-14 2025-01-15 Sanovel Ilac Sanayi ve Ticaret A.S. Film coated tablets of brivaracetam
TR2023015501A1 (en) * 2023-11-22 2025-06-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A MODIFIED-RELEASE TABLET CONTAINING BRIVARACETA
TR2023015500A1 (en) * 2023-11-22 2025-06-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A MODIFIED-RELEASE TABLET COMPOSITION CONTAINING BRIVARACETA

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165796A1 (en) * 2005-01-27 2006-07-27 Alembic Limited Extended release formulation of levetiracetam
WO2006090275A1 (en) * 2005-02-24 2006-08-31 Pfizer Limited Treatment of incontinence
EP1806339A1 (en) * 2005-12-21 2007-07-11 Ucb, S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
WO2007141002A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma, S.A. Co-crystals of pyrrolidinones

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
RU2346996C2 (en) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Improved leaching of base metals
US7930013B2 (en) 2005-06-29 2011-04-19 Compumedics Limited Sensor assembly with conductive bridge
TW200735878A (en) * 2005-11-18 2007-10-01 Astrazeneca Ab Pharmaceutical compositions
PT1954241E (en) * 2005-11-28 2012-06-01 Orexigen Therapeutics Inc Sustained-release formulation of zonisamide
JP2009525953A (en) * 2006-01-11 2009-07-16 テバ ファーマシューティカル インダストリーズ リミティド Sustained release formulation of divalproic acid and its derivatives
JP2006335771A (en) * 2006-09-22 2006-12-14 Takeda Chem Ind Ltd Sustained release medicine and production method thereof
KR20090119959A (en) * 2006-10-12 2009-11-23 아보트 러보러터리즈 Pharmaceutical formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060165796A1 (en) * 2005-01-27 2006-07-27 Alembic Limited Extended release formulation of levetiracetam
WO2006090275A1 (en) * 2005-02-24 2006-08-31 Pfizer Limited Treatment of incontinence
EP1806339A1 (en) * 2005-12-21 2007-07-11 Ucb, S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
WO2007141002A1 (en) * 2006-06-08 2007-12-13 Ucb Pharma, S.A. Co-crystals of pyrrolidinones

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VON ROSENSTIEL ET AL: "Brivaracetam (UCB 34714)", 20061230, vol. 4, no. 1, 30 December 2006 (2006-12-30), pages 84 - 87, XP005735280 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011135430A1 (en) 2010-04-29 2011-11-03 Lupin Limited Controlled release pharmaceutical compositions of brivaracetam
JP2013525417A (en) * 2010-04-29 2013-06-20 ルピン・リミテッド Sustained release pharmaceutical composition of brivaracetam
JP2013537238A (en) * 2010-09-21 2013-09-30 インテクリン・セラピユーテイクス・インコーポレイテツド Anti-diabetic solid pharmaceutical composition
JP2017039739A (en) * 2010-09-21 2017-02-23 インテクリン・セラピユーテイクス・インコーポレイテツド Anti-diabetic solid pharmaceutical composition
US11911510B2 (en) 2017-08-31 2024-02-27 Purdue Pharma L.P Pharmaceutical dosage forms
EP3964201A4 (en) * 2020-07-09 2022-12-28 Shanghai Bocimed Pharmaceutical Co., Ltd. OPHTHALMIC PHARMACEUTICAL COMPOSITION, PROCESS FOR MANUFACTURE THEREOF AND APPLICATION THEREOF
EP4559456A1 (en) 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet of brivaracetam
EP4559457A1 (en) 2023-11-22 2025-05-28 Sanovel Ilac Sanayi ve Ticaret A.S. A modified release tablet composition of brivaracetam

Also Published As

Publication number Publication date
PL2285357T3 (en) 2014-08-29
CA2722093C (en) 2015-04-28
CN102046153A (en) 2011-05-04
CA2722093A1 (en) 2009-12-03
JP2011521927A (en) 2011-07-28
EP2285357B1 (en) 2014-05-07
JP5553452B2 (en) 2014-07-16
ES2465478T3 (en) 2014-06-05
HK1153141A1 (en) 2012-03-23
EP2285357B8 (en) 2014-07-23
US20110091547A1 (en) 2011-04-21
BRPI0912161A2 (en) 2015-10-06
ES2465478T8 (en) 2014-08-22
EP2285357A1 (en) 2011-02-23
US8435564B2 (en) 2013-05-07
CN102046153B (en) 2015-06-17
DK2285357T3 (en) 2014-06-02

Similar Documents

Publication Publication Date Title
CA2722093C (en) Pharmaceutical compositions comprising brivaracetam
EP3417861B1 (en) Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
KR100897890B1 (en) Multilayer tablets containing thiazolidinedione and biguanides and methods for their preparation
EP2391349B1 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
JP5750847B2 (en) Particulate pharmaceutical composition for oral administration of atorvastatin
WO2011111818A1 (en) Sustained release type pharmaceutical composition containing mosapride or salt thereof
JP2009502835A (en) Pharmaceutical composition containing levetiracetam and method for its preparation
CN113939289A (en) Oral solid tablet containing Bruton&#39;s tyrosine kinase inhibitor and preparation method thereof
EP2620140A1 (en) Crizotinib containing compositions
JP2008528456A (en) Novel pharmaceutical composition comprising candesartan cilexetil as lipophilic crystalline substance
CN110917164B (en) Milopalin besylate sustained-release tablets and preparation method thereof
WO2003082261A1 (en) Extended release venlafaxine formulations
WO2006123213A1 (en) Modified release formulations of gliclazide
JP5525453B2 (en) Pharmaceutical composition
US20160022661A1 (en) Dosage Form Comprising Crizotinib
HU227070B1 (en) Immediate release pharmaceutical composition containing ciprofloxacin and process for its production
US20080220064A1 (en) Extended release matrix formulations of morphine
WO2014016371A1 (en) Micronized aleglitazar
HK1153141B (en) Pharmaceutical compositions comprising brivaracetam
JP2014031359A (en) Tablet containing valacyclovir hydrochloride 2-type crystal and method of manufacturing the same
HK1161988B (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980120221.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09753941

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2722093

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7492/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009753941

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011511013

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12993704

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0912161

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101110